906421-01-0|KD-027|N-(2-(dimethylamino)-2-oxoethyl)-2-(4-ethoxy-N-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenylsulfonamido)-N-methylacetamide|-范德生物科技公司

KD-027

NMR下载 COA and HPLC MSDS下载
names：
N-(2-(dimethylamino)-2-oxoethyl)-2-(4-ethoxy-N-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)phenylsulfonamido)-N-methylacetamide
CAS号：
906421-01-0
MDL Number：
MF(分子式)： C25H35N7O6S MW(分子量)： 561.658
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	KD-027
英文别名	KD-027; KD 027; KD027; SLx-2101; SLx 2101; SLx2101.
CAS号	906421-01-0
Inchi	InChI=1S/C25H35N7O6S/c1-8-10-20-26-16(3)23-25(35)27-24(28-32(20)23)18-13-17(11-12-19(18)38-9-2)39(36,37)31(7)15-22(34)30(6)14-21(33)29(4)5/h11-13H,8-10,14-15H2,1-7H3,(H,27,28,35)
InchiKey	KMBGDFWPWSDZTL-UHFFFAOYSA-N
分子式 Formula	C25H35N7O6S
分子量 Molecular Weight	561.658
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	KD-027(CAS:906421-01-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	KD-027, also known as SLx-2101, is a PDE5A inhibitor potentially for the treatment of hypertension.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Paulis L, Rajkovicova R, Simko F. New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? Curr Hypertens Rep. 2015 Jun;17(6):557. doi: 10.1007/s11906-015-0557-x. Review. PubMed PMID: 25893478; PubMed Central PMCID: PMC4412646.

[2]Peak TC, Yafi FA, Sangkum P, Hellstrom WJ. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015 Jun;20(2):263-75. doi: 10.1517/14728214.2015.1021682. Review. PubMed PMID: 25740087.

[3] Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Ther Adv Urol. 2013 Feb;5(1):35-41. doi: 10.1177/1756287212466282. PubMed PMID: 23372609; PubMed Central PMCID: PMC3547533.

[4] Leonardi R, Alemanni M. The management of erectile dysfunction: innovations and future perspectives. Arch Ital Urol Androl. 2011 Mar;83(1):60-2. PubMed PMID: 21585174.

[5] Gur S, Sikka SC, Hellstrom WJ. Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. doi: 10.1517/13543784.17.6.855 . Review. PubMed PMID: 18491987.

6: Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-50. Review. PubMed PMID: 18197727.7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开